Neurocrine Payables Turnover from 2010 to 2024

NBIX Stock  USD 127.11  1.46  1.16%   
Neurocrine Biosciences Payables Turnover yearly trend continues to be fairly stable with very little volatility. Payables Turnover will likely drop to 0.35 in 2024. Payables Turnover is a liquidity ratio that shows how quickly Neurocrine Biosciences pays off its suppliers by dividing total purchases by average accounts payable. View All Fundamentals
 
Payables Turnover  
First Reported
2010-12-31
Previous Quarter
0.36455464
Current Value
0.35
Quarterly Volatility
36.58828439
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Neurocrine Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Neurocrine Biosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 22.4 M, Interest Expense of 7.4 M or Selling General Administrative of 894.2 M, as well as many indicators such as Price To Sales Ratio of 6.48, Dividend Yield of 0.0 or PTB Ratio of 6.13. Neurocrine financial statements analysis is a perfect complement when working with Neurocrine Biosciences Valuation or Volatility modules.
  
Check out the analysis of Neurocrine Biosciences Correlation against competitors.
For more information on how to buy Neurocrine Stock please use our How to Invest in Neurocrine Biosciences guide.

Latest Neurocrine Biosciences' Payables Turnover Growth Pattern

Below is the plot of the Payables Turnover of Neurocrine Biosciences over the last few years. It is a liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable. Neurocrine Biosciences' Payables Turnover historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Neurocrine Biosciences' overall financial position and show how it may be relating to other accounts over time.
Payables Turnover10 Years Trend
Slightly volatile
   Payables Turnover   
       Timeline  

Neurocrine Payables Turnover Regression Statistics

Arithmetic Mean16.13
Coefficient Of Variation226.79
Mean Deviation21.72
Median0.35
Standard Deviation36.59
Sample Variance1,339
Range138
R-Value(0.38)
Mean Square Error1,230
R-Squared0.15
Significance0.16
Slope(3.14)
Total Sum of Squares18,742

Neurocrine Payables Turnover History

2023 0.36
2022 0.34
2021 0.28
2020 0.26
2019 0.18
2018 0.35
2017 0.22

About Neurocrine Biosciences Financial Statements

Neurocrine Biosciences investors use historical fundamental indicators, such as Neurocrine Biosciences' Payables Turnover, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Neurocrine Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Payables Turnover 0.36  0.35 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Neurocrine Stock Analysis

When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.